Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Previously Treated Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer

NCT01999673 is registered in ClinicalTrials.gov with Peregrine Pharmaceuticals as lead sponsor.

NCT NCT01999673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01999673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Previously Treated Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer
Lead sponsor
Peregrine Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2013
Completion date
March 31, 2017
Enrollment
582 (estimated)
Sites
161

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, non-small cell lung cancer, non-small-cell lung cancer metastatic, non-small-cell lung cancer stage iiib, non-small-cell lung cancer stage iv, non-small-cell lung carcinoma, nonsmall cell lung cancer